The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of efficacy.
Hillmen, P Rawstron, A Munir, T Brock, K Vincente, S Jefferson, Y Paterson, K Fox, C Gribben, J Bloor, Adrian
Hillmen, P
Rawstron, A
Munir, T
Brock, K
Vincente, S
Jefferson, Y
Paterson, K
Fox, C
Gribben, J
Bloor, Adrian
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2017
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory Cll shows acceptable safety and promising early indications of efficacy. 2017, 102(s2): 311 Haematologica